Servier, CTI BioPharma in $133.5M Pixuvri Deal
CTI BioPharma entered into an agreement with Servier to develop and commercialize lymphoma drug Pixuvri® (pixantrone).
Partnership Offers Seamless ADC Development and Manufacturing
Fujifilm Diosynth Biotechnologies and Piramal Healthcare in the U.K. are pooling their expertise to offer what they claim is a seamless contract development and manufacturing service for antibody drug conjugates (ADCs).
FDA Gives Abbott a Thumbs-Up for Automated HBV Monitoring Test
Assay can be used with the Abbott m2000 system to understand response to treatment.
Novartis’ AHF Drug Serelaxin Fails Trial Nearly Three Years after FDA...
RELAX-AHF-2 study failed to meet primary endpoints
Magic Mushrooms Break on Through to Biosynthetic Reality
Enzymatic synthesis of psilocybin, the active ingredient of psychedelic mushrooms, has been detailed
Merck & Co. Expands Pipeline in Cancer, Fibrosis, Autoimmune Diseases by...
Merck & Co. plans to acquire Tilos Therapeutics for up to $773 million, in a deal designed to expand the buyer’s cancer, fibrosis, and autoimmune disease pipelines with therapies targeting the latent TGFβ complex.
Complix’ Series A Financing Reaches €7M for Development of Alphabody Therapeutics
Increased investment round follows recently awarded €1.6M grant from Flanders Government.
Advanced Immunotherapeutic Method Shows Promise against Brain Cancer
Researchers develop novel technique to induce a specific type of cell death in brain cancer cells from mice
EU Backs Consortium Dedicated to Protein Kinase Discovery and Development Services
Eurostars-funded Kinomed Partnership will exploit expertise of KinaseDetect, Iota Pharmaceuticals and SARomics Biostructures.
Biotie Regains Asia-Pacific Rights for VAP-1 Antibody Program from Seikagaku
Biotie has changed its strategy of focusing on locomotive diseases to fibrotic diseases.
